๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Isoniazid therapy in Parkinson's disease

โœ Scribed by O. S. Gershanik; M. R. Luquin; O. Scipioni; Dr. J. A. Obeso

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
386 KB
Volume
3
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

โœฆ Synopsis

The effect of isoniazid on levodopa-induced dyskinesias has been evaluated in 20 patients with Parkinson's disease, following a serendipitous observation that choreic dyskinesias induced by levodopa in one parkinsonian patient were markedly reduced during treatment with isoniazid for tuberculous infection. A mean average isoniazid dose of 290 mg was given without any change in current antiparkinsonian treatment. "Benefit of dose" choreic dyskinesias were markedly reduced in 18 patients within the first few weeks of treatment. This effect was accompanied by an intolerable worsening of parkinsonian signs. All patients returned to their basal situation after isoniazid interferes with the therapeutic action of levodopa and dopamine agonists. The precise mechanism by which this action occurred is not known, but several possible explanations are discussed.

๐Ÿ“œ SIMILAR VOLUMES

Initiating therapy in Parkinson's diseas
Initiating therapy in Parkinson's disease
โœ William Weiner; Eric Ahlskog; Stewart Factor; Oksana Suchowersky; Stephen Reich ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 51 KB ๐Ÿ‘ 2 views
Parkinson's disease/Parkinson syndromesโ€”
Parkinson's disease/Parkinson syndromesโ€”therapy: Levodopa
๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 249 KB

Three patients with Parlcinson's disease, optimally treated with levodopdcabidopa (LDKD) tablets, but experiencing severe motor fluctuations, were administered a solution of levodopd carbidopalascorbic acid (LCAS) orally at intervals ranging from 30 to 60 minutes. Patients were rated half-hourly to

Parkinson's disease/Parkinson syndromesโ€”
Parkinson's disease/Parkinson syndromesโ€”therapy: Clozapine
๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 233 KB

Cabergoline ( C b ) is a U-2 ergot derivative with a long active half-life O 4 8 h ) . In a n open rising dose study we added C b to levodopa+inhibitor in 3 0 parkinsonian patients w i t h motor fluctuations. C h m e a n daily dose w a s 13.3(6-20). given once a day. for a mean period of 1 8 . 3 16-

Parkinson's disease/Parkinson syndromesโ€”
Parkinson's disease/Parkinson syndromesโ€”therapy: Miscellaneous
๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 210 KB

r i e d m a n , B r o w n U n i v e r s i t y , P r o v i d e n c e , R h o d e I s l a n d , C. C a l e y , I n s t i t u t e f o r m e n t a l H e a l t h , C r a n s t o n , R h o d e I s l a n d W e r e v i e w e d our e x p e r i e n c e w i t h f l u o x e t i n e in i d i o p a t h i c P a r